MX2017008455A - Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida. - Google Patents

Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida.

Info

Publication number
MX2017008455A
MX2017008455A MX2017008455A MX2017008455A MX2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A MX 2017008455 A MX2017008455 A MX 2017008455A
Authority
MX
Mexico
Prior art keywords
implantation
receptor antagonist
pregnancy
luteal phase
oxytocin receptor
Prior art date
Application number
MX2017008455A
Other languages
English (en)
Inventor
Arce Joan-Carles
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2017008455A publication Critical patent/MX2017008455A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/42—Gynaecological or obstetrical instruments or methods
    • A61B17/425—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation
    • A61B17/435—Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo or ova transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al uso de un antagonista del receptor de oxitocina en hembras que se someten a trasferencia embrionaria como parte de una tecnología de reproducción asistida. En particular, se proporcionan métodos para aumentar la tasa de implantación en curso, aumentar la tasa de embarazos en curso, aumentar la tasa de embarazos clínicos y/o aumentar la tasa de nacidos vivos en un sujeto hembra que se somete a transferencia embrionaria. Específicamente, los antagonistas se liberan en la fase lútea cuando el endometrio es receptivo para la implantación del embrión y/o cuando el embrión ha alcanzado la fase de blastocisto.
MX2017008455A 2014-12-22 2015-12-21 Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida. MX2017008455A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199709.8A EP3037101B1 (en) 2014-12-22 2014-12-22 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
US14/643,307 US9579305B2 (en) 2014-12-22 2015-03-10 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
PCT/NL2015/050893 WO2016105190A1 (en) 2014-12-22 2015-12-21 Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

Publications (1)

Publication Number Publication Date
MX2017008455A true MX2017008455A (es) 2018-04-26

Family

ID=52338895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008455A MX2017008455A (es) 2014-12-22 2015-12-21 Tratamiento con antagonista del receptor de oxitocina en la fase lutea para la implatacion y embarazo en mujeres sometidas a tratamiento con tecnologias de reproduccion asistida.

Country Status (21)

Country Link
US (4) US9579305B2 (es)
EP (2) EP3037101B1 (es)
JP (2) JP6858130B2 (es)
KR (1) KR20170135821A (es)
CN (2) CN113940990A (es)
AU (1) AU2015367900B2 (es)
BR (1) BR112017013521A2 (es)
CA (1) CA2971846A1 (es)
CL (1) CL2017001640A1 (es)
EA (1) EA201791361A1 (es)
ES (1) ES2716862T3 (es)
IL (1) IL253078B (es)
MX (1) MX2017008455A (es)
MY (1) MY181349A (es)
PH (1) PH12017550030A1 (es)
PL (1) PL3037101T3 (es)
SG (1) SG11201705175RA (es)
TW (1) TWI702043B (es)
UA (1) UA125492C2 (es)
WO (1) WO2016105190A1 (es)
ZA (1) ZA201704958B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
EP3164384B1 (en) 2014-07-02 2019-12-04 ObsEva S.A. Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
KR20180099708A (ko) 2016-01-04 2018-09-05 메르크 세로노 에스. 에이. 하이드록시프로필티아졸리딘 카르복사미드 유도체의 알파-아미노 에스테르 및 이의 염 형태, 결정 다형체
ES2898778T3 (es) * 2016-07-21 2022-03-08 ObsEva SA Pautas posológicas de antagonistas de oxitocina para promover la implantación de embriones y prevenir aborto espontáneo
CA3149898A1 (en) 2019-09-03 2021-03-11 Ernest Loumaye Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh) 2020-02-10 2022-11-22 奥布赛瓦股份公司 用于催产素受体拮抗剂疗法的生物标志物
CN114292907A (zh) * 2020-12-15 2022-04-08 苏州亿康医学检验有限公司 用于反复植入失败的生物标志物和诊断与治疗方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
AUPP421298A0 (en) 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
SK8612003A3 (en) * 2001-01-09 2004-03-02 Schering Ag The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment
CN100376289C (zh) * 2001-09-12 2008-03-26 应用研究系统Ars股份公司 人绒毛膜促性腺激素和黄体生成激素在控制性超排卵中的应用
DE60309847T2 (de) 2002-02-27 2007-10-18 Ferring B.V. Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
UA78058C2 (en) * 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
FR2849380A1 (fr) * 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US7111275B2 (en) 2003-08-28 2006-09-19 International Business Machines Corporation Electronic circuit design analysis system
US20070276019A1 (en) 2003-09-18 2007-11-29 Axys Pharmaceuticals, Inc. Haloalkyl Containing Compounds as Cysteine Protease Inhibitors
EP1673355A1 (en) 2003-09-22 2006-06-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
CN101646436B (zh) * 2005-05-10 2012-07-18 辉凌国际制药（瑞士）有限公司 催产素和/或血管升压素的拮抗剂在辅助生殖中的应用
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
KR20120023097A (ko) 2009-05-14 2012-03-12 애들레이드 리서치 앤드 이노베이션 피티와이 리미티드 난모세포의 수집 및 성숙 방법
US9481863B2 (en) 2011-07-01 2016-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining developmental stage of human cumulus cells
US10271876B2 (en) 2011-11-23 2019-04-30 Mezadata Medical Ip Holding Llc Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells
US20130337487A1 (en) 2012-05-31 2013-12-19 Auxogyn, Inc. In vitro embryo blastocyst prediction methods
EP2922475A1 (en) 2012-11-26 2015-09-30 Ferring BV Method and system for diagnosing uterine contraction levels using image analysis
EP3037101B1 (en) 2014-12-22 2019-03-06 Ferring B.V. Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies

Also Published As

Publication number Publication date
JP2021054863A (ja) 2021-04-08
PL3037101T3 (pl) 2019-06-28
AU2015367900B2 (en) 2021-05-13
EP3501533A1 (en) 2019-06-26
US11752157B2 (en) 2023-09-12
US10183029B2 (en) 2019-01-22
ES2716862T3 (es) 2019-06-17
CN107249618B (zh) 2021-11-16
AU2015367900A1 (en) 2017-08-03
US10688106B2 (en) 2020-06-23
PH12017550030A1 (en) 2018-01-15
TW201636016A (zh) 2016-10-16
CN113940990A (zh) 2022-01-18
JP6858130B2 (ja) 2021-04-14
SG11201705175RA (en) 2017-07-28
US20170189415A1 (en) 2017-07-06
US20200352962A1 (en) 2020-11-12
MY181349A (en) 2020-12-21
EP3037101B1 (en) 2019-03-06
CL2017001640A1 (es) 2018-01-26
CN107249618A (zh) 2017-10-13
US20170348325A1 (en) 2017-12-07
ZA201704958B (en) 2019-10-30
KR20170135821A (ko) 2017-12-08
BR112017013521A2 (pt) 2018-03-06
EA201791361A1 (ru) 2017-11-30
UA125492C2 (uk) 2022-04-13
JP7184935B2 (ja) 2022-12-06
US20160175283A1 (en) 2016-06-23
IL253078A0 (en) 2017-08-31
IL253078B (en) 2020-04-30
EP3037101A1 (en) 2016-06-29
TWI702043B (zh) 2020-08-21
US9579305B2 (en) 2017-02-28
JP2018505212A (ja) 2018-02-22
NZ733869A (en) 2020-10-30
WO2016105190A1 (en) 2016-06-30
CA2971846A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
PH12017550030A1 (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
PH12017500014A1 (en) Myo-inositol and one or more probiotic and use thereof
MX2021008858A (es) Vitamina b2 para la diabetes gestacional.
HRP20181794T1 (hr) Cervikalni pesar koji sadrži progesteron za produljeno, neprekidno i kontinuirano oslobađanje, koji se koristi za spriječavanje prijevremenog porođaja
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX2016014913A (es) Dispositivo y formulacion para el tratamiento topico de dolor que afecta a la zona vulvar del organo genital humano femenino.
MX2017001632A (es) Mioinositol y probioticos, y uso de estos.
MY172530A (en) Method for treating gynecological diseases
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
PH12015502160A1 (en) Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women
MX2020007193A (es) Suplemento materno.
IL250212A0 (en) Tungsten salts (vi) for use in the treatment of infertility, to favor normal fertility and reproduction in the female of non-diabetic mammals, as well as to improve the efficiency of assisted reproduction techniques
UA85636U (ru) Способ лечения угрозы преждевременных родов у беременных с многоплодной беременностью препаратом «спаскупрель»
TH180281A (th) การบำบัดของออกซีโตซินรีเซปเตอร์แอนตาโกนิสต์ในระยะหลังไข่ตก สำหรับการฝังตัวและการตั้งครรภ์ในผู้หญิงที่ได้รับเทคโนโลยีที่เกี่ยวกับ การสืบพันธุ์ที่ได้รับการช่วยเหลือ
Gracheva Peculiarities of pregravid preparation of women with non-differentiated connective tissue dysplasia
PH12018502440A1 (en) Angiotensin-1-receptor antagonists
UA78016U (ru) Способ диагностики внутриутробного состояния плода при плацентарной дисфункции в III триместре беременности
UA77310U (ru) Способ оценки готовности организма к родам и состояния плода при доношенной беременности
UA75352U (ru) Способ получения зародышей телят требуемого пола
UA82293U (ru) Способ диагностики преждевременных родов у женщин из группы перинатального риска
RU2013121133A (ru) Способ профилактики задержания последа у коров
WO2015008087A3 (en) Control of uterine contractions
UA106165U (uk) Спосіб лікування фіброзно-кістозної мастопатії у жінок з міомою матки
MX2016011801A (es) Crema de estradiol de dosis baja.
UA74691U (ru) Способ диагностики опухолей молочной железы

Legal Events

Date Code Title Description
FG Grant or registration